Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases

Abstract Antimelanoma differentiation‐associated gene 5 antibody (anti‐MDA5 Ab)‐positive dermatomyositis frequently develops life‐threatening rapidly progressive interstitial lung disease (RP‐ILD). The longitudinal dynamics of antibody titers reflects treatment responses, and negative conversion of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kentaro Awaji, Yoshihide Asano, Yuki Fukui, Tomonori Oka, Tetsuo Toyama, Shinichi Sato
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	antimelanoma differentiation‐associated gene 5 antibody combined immunosuppressive therapy cyclophosphamide intravenous immunoglobulin negative conversion tacrolimus Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/5564906542414311b099628e83d7d24b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5564906542414311b099628e83d7d24b
record_format	dspace
spelling	oai:doaj.org-article:5564906542414311b099628e83d7d24b2021-11-10T05:50:44ZRapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases2574-459310.1002/cia2.12169https://doaj.org/article/5564906542414311b099628e83d7d24b2021-08-01T00:00:00Zhttps://doi.org/10.1002/cia2.12169https://doaj.org/toc/2574-4593Abstract Antimelanoma differentiation‐associated gene 5 antibody (anti‐MDA5 Ab)‐positive dermatomyositis frequently develops life‐threatening rapidly progressive interstitial lung disease (RP‐ILD). The longitudinal dynamics of antibody titers reflects treatment responses, and negative conversion of anti‐MDA5 Ab leads to the prevention of RP‐ILD relapse. Case 1 finally achieved negative conversion of anti‐MDA5 Ab after 18‐month immunosuppressive therapy despite early diagnosis from skin manifestations. Case 2 showed re‐elevation of anti‐MDA5 Ab after tacrolimus discontinuation; immediate restart of tacrolimus recovered it without relapse. These cases suggest that anti‐MDA5 Ab monitoring is essential to determine therapeutic strategy in dermatomyositis patients with RP‐ILD during both initial and maintenance phases.Kentaro AwajiYoshihide AsanoYuki FukuiTomonori OkaTetsuo ToyamaShinichi SatoWileyarticleantimelanoma differentiation‐associated gene 5 antibodycombined immunosuppressive therapycyclophosphamideintravenous immunoglobulinnegative conversiontacrolimusDermatologyRL1-803Immunologic diseases. AllergyRC581-607ENJournal of Cutaneous Immunology and Allergy, Vol 4, Iss 4, Pp 78-81 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antimelanoma differentiation‐associated gene 5 antibody combined immunosuppressive therapy cyclophosphamide intravenous immunoglobulin negative conversion tacrolimus Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
spellingShingle	antimelanoma differentiation‐associated gene 5 antibody combined immunosuppressive therapy cyclophosphamide intravenous immunoglobulin negative conversion tacrolimus Dermatology RL1-803 Immunologic diseases. Allergy RC581-607 Kentaro Awaji Yoshihide Asano Yuki Fukui Tomonori Oka Tetsuo Toyama Shinichi Sato Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases
description	Abstract Antimelanoma differentiation‐associated gene 5 antibody (anti‐MDA5 Ab)‐positive dermatomyositis frequently develops life‐threatening rapidly progressive interstitial lung disease (RP‐ILD). The longitudinal dynamics of antibody titers reflects treatment responses, and negative conversion of anti‐MDA5 Ab leads to the prevention of RP‐ILD relapse. Case 1 finally achieved negative conversion of anti‐MDA5 Ab after 18‐month immunosuppressive therapy despite early diagnosis from skin manifestations. Case 2 showed re‐elevation of anti‐MDA5 Ab after tacrolimus discontinuation; immediate restart of tacrolimus recovered it without relapse. These cases suggest that anti‐MDA5 Ab monitoring is essential to determine therapeutic strategy in dermatomyositis patients with RP‐ILD during both initial and maintenance phases.
format	article
author	Kentaro Awaji Yoshihide Asano Yuki Fukui Tomonori Oka Tetsuo Toyama Shinichi Sato
author_facet	Kentaro Awaji Yoshihide Asano Yuki Fukui Tomonori Oka Tetsuo Toyama Shinichi Sato
author_sort	Kentaro Awaji
title	Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases
title_short	Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases
title_full	Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases
title_fullStr	Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases
title_full_unstemmed	Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases
title_sort	rapidly progressive interstitial lung disease associated with dermatomyositis—longitudinal course of anti‐mda5 antibody titer in two cases
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/5564906542414311b099628e83d7d24b
work_keys_str_mv	AT kentaroawaji rapidlyprogressiveinterstitiallungdiseaseassociatedwithdermatomyositislongitudinalcourseofantimda5antibodytiterintwocases AT yoshihideasano rapidlyprogressiveinterstitiallungdiseaseassociatedwithdermatomyositislongitudinalcourseofantimda5antibodytiterintwocases AT yukifukui rapidlyprogressiveinterstitiallungdiseaseassociatedwithdermatomyositislongitudinalcourseofantimda5antibodytiterintwocases AT tomonorioka rapidlyprogressiveinterstitiallungdiseaseassociatedwithdermatomyositislongitudinalcourseofantimda5antibodytiterintwocases AT tetsuotoyama rapidlyprogressiveinterstitiallungdiseaseassociatedwithdermatomyositislongitudinalcourseofantimda5antibodytiterintwocases AT shinichisato rapidlyprogressiveinterstitiallungdiseaseassociatedwithdermatomyositislongitudinalcourseofantimda5antibodytiterintwocases
_version_	1718440556810469376

Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases

Ejemplares similares